Substance / Medication

Podophyllotoxin

Overview

Active Ingredient
podofilox
RxNorm CUI
8463

Indications

not PRECAUTIONS Condylox Gel 0.5% is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product isindicated in the treatment of mucous membrane warts (see).

Labeler: Allergan, Inc.Updated: 2024-01-29T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Condylox Gel 0.5% is contraindicated for patients who develop hypersensitivity or intolerance to any components of the formulation.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Plant Origin Source, Content Profile and Bioactivity of Podophyllotoxin as an Important Natural Anticancer Agent.
Liu Wei, Zhao Dan, Yin Dongxue et al. · Chem Biodivers · 2025
PMID: 39562516Meta-Analysis
The Effects of Podophyllotoxin Derivatives on Noncancerous Diseases: A Systematic Review.
Strus Piotr, Sadowski Karol, Ploch Weronika et al. · Int J Mol Sci · 2025
PMID: 39940726Meta-AnalysisFull text (PMC)
Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata.
Yan Jun, Chen Sheng-Li, Wang Hai-Na et al. · Dermatology · 2006
PMID: 17033171Meta-Analysis
Clinical Efficacy of Combination Therapy with Podophyllotoxin and Liquid Nitrogen Cryotherapy in the Treatment of Genital Warts in Men.
Golušin Zoran, Jovanović Marina, Matić Milan et al. · Acta Dermatovenerol Croat · 2019
PMID: 31969238RCT
Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Gilson Richard, Nugent Diarmuid, Bennett Kate et al. · Health Technol Assess · 2020
PMID: 32975189ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Podophyllotoxin (substance)
SNOMED CT
76575003
UMLS CUI
C0032334
RxNorm CUI
8463
Labeler
Allergan, Inc.

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.